Countries Request a quote
CJC-1295 + GHRP-6 Blend — Alphagenics vial
Growth Hormone

CJC-1295 + GHRP-6 Blend

CJC-1295 / GHRP-6

Combination of a GHRH analog + GH secretagogue (GHS-R1a)

Components2
Total0.8mg / 1.7mg
Available presentations
Request a quote Quick guide Research protocol View evidence Reconstitution calculator Physician login

About CJC-1295 + GHRP-6 Blend

This presentation combines two peptides that act on complementary pathways of growth hormone release.

CJC-1295 is a tetrasubstituted GHRH (1-29) analog that acts on the GHRH receptor of the pituitary; the version with drug affinity complex (DAC) binds covalently to albumin and extends its half-life to several days. GHRP-6 acts on the ghrelin receptor (GHS-R1a). In the literature, simultaneous stimulation of both pathways has been associated with synergistic GH release, greater than the sum of each stimulus separately.

Quick guide · 5 key points

CJC-1295 + GHRP-6: two signals for GH

This blend pairs a long-acting GHRH analog with a ghrelin-receptor secretagogue, two separate pathways for growth hormone (GH) release. Here are five things the research shows.

View research protocolProtocol (PDF) Open guide (PDF) Download guide
  1. 1

    Two receptors, two signals

    CJC-1295 is a GHRH analog that acts on the pituitary GHRH receptor. GHRP-6 acts on the GH secretagogue receptor, the same one used by ghrelin. These are two independent pathways that control GH release.1,2,3,5,6

    CJC-1295 (DAC)GHRH analog. Binds to albumin, so its effect lasts days.
    GHRP-6Activates the ghrelin receptor. In rats, GH rises within minutes and returns to baseline in about 2 hours.
    2 pathwaysGHRH and ghrelin: two independent signals for GH release
  2. 2

    Why combine them: synergy

    In healthy men, GHRH given with GHRP-6 at submaximal doses has been shown to produce synergistic GH release, greater than either peptide alone. That study used natural GHRH, not CJC-1295; there are no published studies of this specific blend.1

    SynergyGH with GHRH + GHRP-6, vs each one alone
  3. 3

    CJC-1295: GH and IGF-1 raised for days

    In healthy adults, a single dose of CJC-1295 was associated with 2- to 10-fold higher GH for 6 days or more and 1.5- to 3-fold higher IGF-1 for 9 to 11 days. Its estimated half-life was 5.8 to 8.1 days.4

    5.8–8.1 daysEstimated half-life of CJC-1295 in healthy adults
  4. 4

    GH keeps its pulsing rhythm

    In healthy men aged 20 to 40, one week after a dose of CJC-1295, GH kept its pulsatile pattern, with the same pulse frequency. Baseline GH rose 7.5-fold, mean GH by 46% and IGF-1 by 45%.2

    7.5×Rise in baseline (trough) GH one week later
  5. 5

    What is known about safety

    In CJC-1295 trials in healthy adults, no serious adverse reactions were reported. With GHRP-6 in healthy men there were no clinical adverse effects, but at the highest dose prolactin and cortisol rose about 2-fold. Safety data come from each component on its own.4,1

    ≈ 2×Prolactin and cortisol at the highest GHRP-6 dose
References
  1. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. PMID 2108187
  2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID 17018654
  3. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PMID 8688086
  4. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683
  5. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. PMID 10604470
  6. Bowers CY, et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 1984;114(5):1537-45. PMID 6714155

Components per vial

Reference amounts of the formulation. The physicochemical data correspond to each individual peptide.

CJC-1295 (DAC)

0.8 mg
YaDAIFTQSYRKVLAQLSARKLLQDILSRK(maleimidopropionyl)NH2 (a = D-Ala)
Molecular formula
C165H269N47O46
Molecular weight
3647.2 g/mol
CAS number
446262-90-4
PubChem CID
91971820
Length
30 amino acids

GHRP-6

1.7 mg
HisDTrpAlaTrpDPheLysNH2
Molecular formula
C46H56N12O6
Molecular weight
873.0 g/mol
CAS number
87616-84-0
PubChem CID
9919153
Length
6 amino acids

Five findings from studies

Summary of results reported in the scientific literature. Each finding describes what was observed in the cited study, in its specific population and conditions; it does not constitute a therapeutic indication.

  1. Clinical study

    In healthy adults, a single dose of CJC-1295 has shown sustained increases in plasma GH (2- to 10-fold for 6 days or more) and in IGF-1 (1.5- to 3-fold for 9 to 11 days).

    Teichman SL et al. J Clin Endocrinol Metab. 2006;91:799-805 · PMID 16352683
  2. Clinical study

    In healthy men, after a dose of CJC-1295, GH secretion has been observed to retain its pulsatile pattern, with a marked increase in basal (trough) secretion and in IGF-1.

    Ionescu M, Frohman LA. J Clin Endocrinol Metab. 2006;91:4792-4797 · PMID 17018654
  3. Preclinical

    In GHRH-deficient mice, daily administration of CJC-1295 has normalized body growth; with 48- or 72-hour intervals the effect was smaller.

    Alba M et al. Am J Physiol Endocrinol Metab. 2006;291:E1290-E1294 · PMID 16822960
  4. Clinical study

    In healthy men, the combination of GHRH with GHRP-6 at submaximal doses has shown synergistic GH release, greater than that of each peptide separately.

    Bowers CY et al. J Clin Endocrinol Metab. 1990;70:975-982 · PMID 2108187
  5. Preclinical

    In a porcine model of myocardial infarction, GHRP-6 has been associated with a 78% reduction in infarct mass versus saline.

    Berlanga J et al. Clin Sci (Lond). 2007;112:241-250 · PMID 16989643

More in Growth Hormone

SermorelinIpamorelinTesamorelinGHRP-2